| Autor: |
DeClue RW; ConcertAI, Cambridge, MA 02138, USA., Szamreta EA; Merck & Co., Inc., Rahway, NJ 07065, USA., Gautam S; ConcertAI, Cambridge, MA 02138, USA., Fisher MD; ConcertAI, Cambridge, MA 02138, USA., Monberg MJ; Merck & Co., Inc., Rahway, NJ 07065, USA. |
| Abstrakt: |
Aim: Real-world data on treatment patterns and outcomes of advanced ovarian cancer (OC) patients since bevacizumab approval in first-line (1L) OC treatment were assessed. Materials & methods: In this descriptive retrospective study using the ConcertAI Oncology Dataset, patient characteristics, treatment patterns and real-world progression-free survival (rwPFS) from start of 1L were evaluated among patients diagnosed with advanced OC between 2011-2020. Treatment data from structured sources were confirmed and/or supplemented by human review of unstructured data. Results: Median rwPFS for bevacizumab and non bevacizumab cohorts was 17.3 months (95% CI: 14.9, 20.4) and 15.7 months (95% CI: 12.3, 29.1), respectively. Patients with ≥10 doses during 1L had higher median rwPFS compared with patients receiving 3-9 doses. Conclusion: This real-world study suggests benefits of bevacizumab treatment in advanced OC were primarily experienced by patients who received ≥10 doses in 1L. |
